Brendan Haberle’s practice focuses on technology transactions within the life sciences industry. Brendan leverages his training and prior experience in laboratory science and technical analysis to advise companies on technology licensing, collaborations and other strategic intellectual property transactions, as well as regarding intellectual property matters within corporate transactions such as public offerings and mergers and acquisitions.

Download full bio 


  • Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche 

  • Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion 

  • Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies 

  • Shoreline Biosciences Enters Collaboration With BeiGene to Develop Genetically Modified Cell Therapies 

  • Shoreline Enters Partnership with Kite 


  • University of Arizona, James E. Rogers College of Law
    JD, magna cum laude, 2015

  • Harvey Mudd College
    BS, Physics
    with distinction, 2005

Admissions & Credentials


U.S. Patent and Trademark Office